The mRNA therapeutics and vaccines segment
Post the onset of the COVID-19 pandemic, mRNA therapeutics and vaccines have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as infectious diseases, oncological disorders, genetic disorders and other disorders.

mRNA therapeutics and vaccines have emerged as a promising alternative to conventional treatment approaches. During our research, we were able to identify more than 195 mRNA therapeutics and vaccines that have either been marketed or are being developed in clinical, preclinical and discovery stages for the treatment of various diseases. Driven by the growing interest of various stakeholders and encouraging clinical research results, the overall mRNA therapeutics market and mRNA vaccines market is anticipated to witness consistent growth, till 2035.


To request a sample copy / brochure of this report, please visit


Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies. It is worth highlighting that there is a significant rise in the interest of stakeholders in mRNA vaccines domain segment; this can be validated by the increase in partnership and funding activity within this domain.


Given the numerous benefits of mRNA therapeutics and the increased demand for vaccines as a result of the recent COVID-19 pandemic, we believe that this market will experience significant growth in the near future. During our research, we came across around 180 ongoing and planned clinical trials focused on mRNA therapeutics and vaccines. There was a steady increase (CAGR of 66%) in the number of clinical trials registered for the evaluation of mRNA-based drugs, during the period 2017-2021. This can be attributed to the incessant efforts of several industry players that are actively evaluating mRNA therapies for the treatment of a myriad of disease indications. It is also worth highlighting that 47 trials were registered in 2022.


For additional details, please visit or email


You may also be interested in the following titles:

1.       RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035

2.       Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035


About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.



Ben Johnson

+1 (415) 800 3415